Role of the Wnt/β-catenin network in regulating hematopoiesis

Archivum Immunologiae et Therapiae Experimentalis

Volumn 56, Issue 4, 2008, Pages 257-266

  Wilusz, Mirosława ^a   Majka, Marcin ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

catenin; Hematopoiesis; Stem cells; Tumor cells; Wnt

Indexed keywords

BETA CATENIN; CADHERIN; GROWTH FACTOR RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; WNT PROTEIN;

CALCIUM CELL LEVEL; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL POLARITY; CELL PROLIFERATION; CELL SURVIVAL; DROSOPHILA; GENE EXPRESSION; GENE MUTATION; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; LEUKEMIA; LYMPHOMA; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BETA CATENIN; CADHERINS; HEMATOLOGIC DISEASES; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 50649096986     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-008-0029-y     Document Type: Review

References (110)

1. Austin T. W., Solar G., Matthews W. and Liem L. (1997): A role for the Wnt gene family in hematopoiesis: expansion of multilineage progenitor cells. Blood, 89, 3624-3635.
2. Baba Y., Garrett K. P. and Kincade P. W. (2005): Constitutively active beta-catenin confers multilineage differentiation potential on lymphoid and myeloid progenitors. Immunity, 23, 599-609.
3. Baba Y., Yokota T., Spits H., Garrett K. P., Hayashi S. and Kincade P. W. (2006): Constitutively active beta-catenin promotes expansion of multipotent hematopoietic progenitors in culture, J. Immunol., 177, 2294-2303.
4. Bafico A., Liu G., Yaniv A., Gazit A. and Aaronson S. A. (2001): Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat. Cell Biol., 3, 683-686.
5. Baggiolini M., Dewald B. and Moser B (1997): Human chemokines: an update. Annu. Rev. Immunol., 15, 675-705.
6. Beck S. W. (1994): Hematology. In Beck S. W.: Hematopoiesis. MIT Press, pp. 1-22.
7. Behrens J., von Kries J. P., Kuhl M, Bruchn L., Wedlich B., Grosschedl R. and Birchmeier W. (1996): Functional interaction of beta-catenin with the transcription factors LEF-1. Nature, 382, 638-642.
8. Bhanot P., Brink M., Samos C. H., Hsieh J. C., Wang Y., Macke J. P., Andrew D., Nathans J. and Nusse R. (1996): A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature, 18, 225-230.
9. Cadigan K. M. and Liu Y. I. (2006): Wnt signaling: complexity at the surface. J. Cell Sci., 119, 395-402.
10. Casagrande G., Te Kronnie G. and Basso G. (2006): The effects of siRNA-mediated inhibition of E2A-PBX1 on EB-1 and Wnt16b expression in the 697 pre-B leukemia cell line. Haematologica, 91, 765-771.
11. Chim C. S., Chan W. W., Pang A. and KwongY. L. (2006): Preferential methylation of Wnt inhibitory factor-1 in acute promyelocytic leukemia: an independent poor prognostic factor. Leukemia, 20, 907-909.
12. Chim C. S., Fung T. K., Wong K. F., Lau J. S. and Liang R. (2006): Infrequent Wnt inhibitory factor-1 (Wif-1) methylation in chronic lymphocytic leukemia. Leuk. Res., 30, 1135-1139.
13. Choi S. and Han J. (2002): Xenopus Cdc42 regulates convergent extension movements during gastrulation through Wnt/Ca2+ signaling pathway. Dev. Biol., 244, 342-357.
14. Clapper M. L., Coudry J. and Chang W. (2004): β-Catenin-mediated signaling: a molecular target for early chemopreventive intervention. Mutat. Res., 555, 97-105
15. Cobas M., Radtke F., Wilson A. and Ernst B. (2004): β-Catenin is dispensable for hematopoiesis and lymphopoiesis. J. Exp. Med., 199, 221-229.
16. Coudreuse D. and Korswagen H. C. (2007): The making of Wnt: new insights into Wnt maturation, sorting and secretion. Development, 134, 3-12.
17. Derksen P. W., Tjin E., Meijer H. P., Klok M. D., MacGillavry H. D., Oers M. H., van Lokhorst H. M., Bloem A. C., Nusse R., Neut R., van der Spaargaren M. and Pals S. T. (2004): Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc. Natl. Acad. Sci. USA, 101, 6122-6127.
18. Diarra D., Stolina M., Polzer K., Zwerina J., Ominsky M. S., Dwyer D., Korb A., Smolen J. S. and Scheinecker C. (2007): Dickkopf-1 is a master regulator of joint remodeling. Nat. Med., 13, 156-163.
19. Døsen G., Tenstad E., Nygren M. K., Stubberud H., Funderud S. and Rian E. (2006): Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis. BMC Immunol., 7, 13.
20. Eisenberg L. M. and Eisenberg C. A. (2006): Wnt signal transduction and the formation of the myocardium. Dev. Biol., 293, 305-315.
21. Fujii N., You L., Xu Z., Uematsu K., Shan J., He B., Mikami I., Edmondson L. R., Neale G., Zheng J., Guy R. K. and Jablons D. M. (2007): An antagonist of Dishevelled protein-protein interaction suppresses {beta}-catenin-dependent tumor cell growth. Cancer Res., 67, 573-579.
22. Gazit A., Yaniv A., Bafico,A., Pramila T., Igarashi M., Kitajewski J. and Aaronson S. A. (1999): Human frizzled 1 interacts with transforming Wnts to transduce a TCF dependent transcriptional response. Oncogene, 18, 5959-5966.
23. Giese K, Amsterdam A. and Grosschedl R. (1991): DNA-binding properties of the HMG domain of the lymphoid-specific transcriptional regulator LEF-1. Genes Dev., 5, 2567-2578.
24. Giese K., Cox J. and Grosschedl R. (1992): The HMG domain of lymphoid enhancer factor 1 bends DNA and facilitates assembly of functional nucleoprotein structures. Cell, 69, 185-195.
25. Gou Z., Dose M., Kovalovsky D., Chang., O'Neil J., Look T., Boehmer H., Khazaie K. and Gounari F. (2007): β-Catenin stabilization stalls the transition from double-positive to single-positive stage and predispose thymocytes to malignant transformation. Blood, 109, 5463-5472.
26. Gutierrez N. C., Ocio E. M., de las Rivas J., Maiso P., Delgado M., Ferminan E., Arcos M. J. Sanchez, M. L. Hernandez J. M. and San Miguel J. F. (2007): Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia, 21, 541-549.
27. Habas R. and Dawid I. B. (2005): Dishevelled and Wnt signaling: is the nucleus the final frontier? J. Biol., 4, 2.
28. Hao X., Tomlinson I., Ilyias M., Palazzo J. P. and Talbot I. C. (1997): Reciprocity between membranous and nuclear expression of β-catenin in colorectal tumours. Virchows Arch., 431, 167-172.
29. Harris T. and Peifer M. (2005): Decisions, decisions: β-catenin chooses between adhesion and transcription. Trends Cell Biol., 15, 234-237.
30. Hiendlmeyer E., Regus S., Wassermann S., Hlubek F., Haynl A., Dimmler A., Koch C., Knoll C., van Beest M., Reuning U., Brabletz T., Kirchner T. and Jung A. (2004): β-Catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors. Cancer Res., 64, 1209-1214.
31. Howe D. and Bromidge T. (2006): Variation of LEF-1 mRNA expression in low-grade B-cell non-Hodgkin's lymphoma. Leuk. Res., 30, 29-32.
32. Hsieh J. C., Rattner A., Smallwood P. M. and Nathans J. (1999): Biochemical characterization of Wnt-Frizzled interactions using a soluble, biologically active vertebrate Wnt protein. Proc. Natl. Acad. Sci. USA, 96, 3546-3551.
33. Huelsken J. and Behrens J. (2002): The Wnt signaling pathways. J. Cell Sci., 115, 3977-3978.
34. 2+ pathway to antagonize Wnt/β-catenin signaling. Mol. Cell. Biol., 23, 131-139.
35. Jamieson C. H., Ailles L. E., Dylla S. J., Muijtjens M., Jones C., Zehnder J. L., Gotlib J., Li K., Manz M. G., Keating A., Sawyers C. L. and Weissman I. L. (2004): Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med., 351, 634-636.
36. Janssens N., Janicot M. and Perera T. (2006): The Wnt-dependent signaling pathways as target in oncology drug discovery. Invest. New Drugs, 24, 263-280.
37. Jeannet G., Scheller M., Scarpellino L., Duboux S., Gardiol N., Back J., Kuttler F., Malanchi I., Birchmeier W., Leutz A., Huelsken J. and Held W. (2008): Long-term, multilineage hematopoiesis occurs in the combined absence of {beta}-catenin and {gamma}-catenin. Blood., 111, 142-149.
38. Katoh M. (2005): WNT/PCP signaling pathway and human cancer (review). Oncol. Rep., 14, 1583-1588.
39. Katoh M. and Katoh M. (2006): Cross-talk of WNT and FGF signaling pathways at GSK3beta to regulate beta-catenin and SNAIL signaling cascades. Cancer Biol. Ther., 5, 1059-1064.
40. Kawano Y. and Kypta R. (2003): Secreted antagonists of the Wnt signalling pathway. J. Cell Sci., 116, 2627-2634.
41. Kikuchi A., Yamamoto H. and Kishida S (2007): Multiplicity of the interactions of Wnt proteins and their receptors. Cell. Signal., 19, 659-671.
42. Kim K., Pang K. M., Evans M. and Hay E. D. (2000): Overexpression of β-catenin induces apoptosis independent of its transactivation function with LEF-1 or the involvement of major G1 cell cycle regulators. Mol. Biol. Cell, 11, 3509-3523.
43. Kim S., Xu X., Hecht A. and Boyer T.G. (2006): Mediator is a transducer of Wnt/beta-catenin signaling. J. Biol. Chem., 281, 14066-14075.
44. Kirstetter P., Anderson K., Porse B., Jacobsen S. E. and Nerlov C. (2006): Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat. Immunol., 7, 1048-1056.
45. Koch U., Wilson A., Cobas M., Kemler R., Macdonald H. R. and Radtke F. (2008): Simultaneous loss of {beta}- and {gamma}-catenin does not perturb hematopoiesis or lymphopoiesis. Blood,111, 160-164.
46. Kohn A. D. and Moon R. T. (2005): Wnt and calcium signaling: β-catenin-independent pathways. Cell Calcium, 38, 439-446.
47. Kramps T., Peter O., Brunner E., Nellen D., Froesch B., Chatterjee S., Murone M., Zullig S. and Basler K. (2002): Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell, 109, 47-60.
48. Kühl M., Sheldahl L.C., Park M., Miller J. R. and Moon R. T. (2000): The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet., 16, 279-283.
49. Li F., Chong Z. Z. and Maiese K. (2005): Vital elements of the Wnt-Frizzled signaling pathway in the nervous system. Curr. Neurovasc. Res., 2, 331-340.
50. Liang H., Chen Q., Coles A.H., Anderson S.J., Pihan G., Bradley A. Bradley A., Gerstein R., Jurecic R. and Jones S. N. (2033): Wnt5 inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell, 4, 349-360.
51. Lu D., Zhao Y., Tawatao R., Cottam H. B., Sen M., Leoni L. M., Kipps T. J., Corr M., Carson D. A. (2004): Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA, 101, 3118-3123.
52. Luo Y., Cai J., Xue H., Mattson M. P. and Rao M. S. (2006): SDF1alpha/CXCR4 signaling stimulates beta-catenin transcriptional activity in rat neural progenitors. Leurosci. Lett., 398, 291-295.
53. Ma Y., Cui W., Yang J., Qu J., Di C., Amin H.M., Lai R., Ritz J., Krause D. S. and Chai L. (2006): SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood, 108, 2726-2735.
54. Majka M., Drukala J., Lesko E., Wysoczynski M., Jenson A. B. and Ratajczak M. Z. (2006): SDF-1 alone and in cooperation with HGF regulates biology of human cervical carcinoma cells. Folia Histochem. Cytobiol., 44, 155-164.
55. McWhirter J. R., Neuteboom S. T., Wancewicz E. V., Monia B. P, Downing J. R. and Murre C. (1999): Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia. Proc. Natl. Acad. Sci. USA, 96, 11464-11469.
56. Mikami I., You L., He B., Xu Z., Batra S., Lee A., Mazieres J., Reguart N., Uematsu K., Koizumi K. and Jablons D. M. (2005): Efficacy of Wnt-1 monoclonal antibody in sarcoma cells. BMC Cancer, 5, 53.
57. Monga S. P., Mars W. M., Pediaditakis P., Bell A., Mule K., Browen W. C., Wang X., Zarnegar R. and Michalopoulos G. K. (2002): Hepatocyte growth factor induces Wnt-independent nuclear translocation of β-catenin after Met-β-catenin dissociation in hepatocytes. Cancer Res., 62, 2064-2071.
58. Moon R. T., Bowerman B., Boutros M. and Perrimon N. (2002): The promise and perils of Wnt signaling through β-catenin. Science, 296, 1644-1646.
59. Moon R. T., Kohn A. D., De Ferrari F. and Kayakas A. (2004): Wnt and β-catenin signaling: diseases and therapies. Nature, 5, 689-699.
60. Morrison J. A., Gulley M. L., Pathmanathan R. and Raab-Traub N. (2004): Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res., 64, 5251-5260.
61. Morrison S. J., Uchida N. and Weissman I. L. (1995): The biology of hematopoietic stem cells. Cell Dev. Biol., 11, 35-71.
62. Muller-Tidow C., Steffen B., Cauvet T., Tickenbrock L., Ji P., Diederichs S., Sargin B., Kohler G., Stelljes M., Puccetti E., Ruthardt M., deVos S., Hiebert S. W., Koeffler H. P., Berdel W. E. and Serve H. (2004): Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol. Cell. Biol., 24, 2890-2904.
63. Mulroy T., McMahon J. A., Burakoff S. J., McMahon A. P. and Sen J. (2002): Wnt-1 and Wnt-4 regulate thymic cellularity. Eur. J. Immunol., 32, 967-971.
64. Nelsson W. J. and Nusse R. (2004): Convergence of Wnt, β-catenin, and cadherin pathways. Science, 303, 1483-1487.
65. Nemeth M. J. and Bodine D. M. (2007): Regulation of hematopoiesis and the hematopoietic stem cell niche by Wnt signaling pathways. Cell Res., 17, 746-758.
66. Nemeth M. J., Topol L., Anderson S. M., Yang Y. and Bodine D. M. (2007): Wnt5a inhibits canonical Wnt signaling in hematopoietic stem cells and enhances repopulation. Proc. Natl. Acad. Sci. USA, 104, 15436-15441.
67. Niehrs C. (2006): Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene, 25, 7469-7481.
68. Noordermeer J., Klingensmith J., Perrimon N. and Nusse R. (1994): Dishevelled and armadillo act in the wingless signalling pathway in Drosophila. Nature, 367, 80-83.
69. Nusse R., van Ooyen A., Cox D., Fung Y. K. and Varmus H. (1984): Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature, 307, 131-136.
70. Nygren M. K., Dosen G., Hystad M. E., Stubberud H., Funderud S. and Rian E. (2007): Wnt3A activates canonical Wnt signalling in acute lymphoblastic leukaemia (ALL) cells and inhibits the proliferation of B-ALL cell lines. Br. J. Haematol., 136, 400-413.
71. Okamura R. M., Sigvardsson M., Galceran J., Clevers H. and Grosschedl R. (1998): Redundant regulation of T cell differentiation and TCR alpha gene expression by the transcription factors LEF-1 and TCF-1. Immunity, 8, 11-20.
72. Passequé E., Jamieson C., Ailles L. and Weissman I. (2003): Normal and leukemic hematopoiesis: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc. Natl. Acad. Sci. USA, 100, 11842-11849.
73. Pazianos G., Uqoezwa M. and Reya T. (2003): The elements of stem cell self-renewal: A genetic perspective. Biotechniques, 35, 1240-1247.
74. Peifer M. and Polakis P. (2000): Wnt signaling in oncogenesis and embryogenesis - look outside the nucleus. Science, 287, 1606-1609.
75. Phiel C. J. and Klein P. S. (2001): Molecular targets of lithium action. Annu. Rev. Pharmacol. Toxicol., 41, 789-813.
76. Qiang Y. W., Endo Y., Rubin J. S. and Rudikoff S. (2003): Wnt signaling in B-cell neoplasia. Oncogene, 22, 1536-1545.
77. Ress A. and Moelling K. (2005): Bcr is a negative regulator of the Wnt signaling pathway. EMBO Rep., 6, 1095-1100.
78. Reya T. and Clevers H. (2005): Wnt signaling in stem cells and cancer. Nature, 424, 843-850.
79. Reya T., Duncan A. W., Ailles L., Domen J., Scherer D. C., Willert K., Hintz L., Nusse R. and Weissman I. L. (2003): A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature, 423, 409-414.
80. Reya T., O'Riordan M., Okamura R., Devaney E., Willert K., Nusse R. and Grosschedl R. (2000): signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity, 13, 15-24.
81. Rizzatti E. G., Flacao R. P., Panepucci R. A., Proto-Siquera R., Anselmo-Lima W. T., Okamoto O. K. and Zago M. A. (2005): Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT, and TGFbeta signaling pathways. Br. J. Haematol., 130, 516-526.
82. Saneyoshi T., Kume S., Amasaki Y. and Mikoshiba K. (2002): The Wnt/calcium pathway activates NF-AT and promotes ventral cell fate in Xenopus embryos. Nature, 417, 295-299.
83. Scheller M., Huelsken J., Rosenbauer F., Taketo M. M., Birchmeier W., Tenen D. G. and Leutz A. (2006): Hematopoietic stem cell and multilineage defects generated by constitutive β-catenin activation. Nat. Immunol., 7, 1037-1047.
84. Sharma R. P. and Chopra V. L. (1976): Effect of the Wingless (wg1) mutation on wing and haltere development in Drosophila melanogaster. Dev. Biol., 48, 461-465.
85. Simon M., Grandage V. L., Linch D. C. and Khwaja A. (2005): Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene, 24, 2410-2420.
86. Singh A. M., Li F.Q., Hamazaki T., Kasahara H., Takemaru K. I. and Terada N. (2007): Chibby, an antagonist of the Wnt/[beta]-catenin pathway, facilitates cardiomyocyte differentiation of murine embryonic stem cells. Circulation, 115, 617-626.
87. Staal F. J. and Clevers H. C. (2003): Wnt signaling in the thymus. Curr. Opin. Immunol., 15, 204-208.
88. Staal F. J., Meeldijk J., Moerer P., Jay P., van de Weert B. C., Vainio S., Nolan G. P. and Clevers H. (2001): Wnt signaling is required for thymocyte development and activates tcf-1 mediated transcription. Eur. J. Immunol., 31, 285-293.
89. Steelman C. A., Recknor J. C., Nettleton D. and Reecy J. M. (2006): Transcriptional profiling of myostatin-knockout mice implicates Wnt signaling in postnatal skeletal muscle growth and hypertrophy. FASEB, 20, 580-582.
90. Stoick-Cooper C. L., Weidinger G., Riehle K. J., Hubbert C., Major M. B., Fausto N. and Moon R. T. (2007): Distinct Wnt signaling pathways have opposing roles in appendage regeneration. Development, 134, 479-489.
91. Tu X., Joeng K. S., Nakayama K. I., Nakayama K., Rajagopal J., Carroll T. J., McMahon A. P. and Long F. (2007): Noncanonical Wnt signaling through G protein-linked PKCdelta activation promotes bone formation. Dev. Cell, 12, 113-127.
92. Turashvili G., Bouchal J., Burkadze G. and Kolar Z. (2006): Wnt signaling pathway in mammary gland devel -opment and carcinogenesis. Pathobiology, 73, 213-223.
93. Unterseher F., Hefele J. A., Giehl K., De Robertis E. M., Wedlich D. and Schambony A. (2004): Paraxial protocadherin coordinates cell polarity during convergent extension via Rho A and JNK. EMBO J., 23, 3259-3269.
94. Uren A., Reichsman F., Anest V., Taylor W. G., Muraiso K., Bottaro D. P., Cumberledge S. and Rubin J. S. (2000): Secreted frizzled-related protein-1 binds directly to Wingless and is a biphasic modulator of Wnt signaling. J. Biol. Chem., 275, 4374-4382.
95. Van Den Berg D. J., Sharma A. K., Bruno E. and Hoffman R. (1998): Role of members of the Wnt gene family in human hematopoiesis. Blood, 92, 3189-3202.
96. Van der Wetering, M., de Lau W. and Clevers H. (2002): Wnt signaling and lymphocyte development. Cell, 109, 13-19.
97. Van Ooyen A. and Nusse R. (1984): Structure and nucleotide sequence of the putative mammary oncogene int-1; proviral insertions leave the protein-encoding domain intact. Cell, 39, 233-240.
98. Veeman M. T., Axelrod J. D. and Moon R. T. (2003): Second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. Dev. Cell, 5, 367-377.
99. Veeman M. T., Slusarski D. C., Kaykas A., Louie S. H. and Moon R. T. (2003): Zebrafish prickle, a modulator of noncanonical wnt/fz signaling, regulates gastrulation movements. Curr. Biol., 13, 680-685.
100. Wallingford J. B., Fraser S. E. and Harland R. M. (2002): Convergent extension: the molecular control of polarized cell movement during embryonic development. Dev. Cell, 2, 695-706.
101. Wang H., Gilbert J. B., Bautch V. L., Wang D. Z., Wainwright B. J., Kirby S. L. and Patterson C. (2007): Wnt2 coordinates the commitment of mesoderm to hematopoietic, endothelial, and cardiac lineages in embryoid bodies. Biol. Chem., 282, 782-791.
102. Weerkamp F., Baert M. R., Naber B., Koster E. E., de Haas E., Atkuri K., van Dongen J. J., Herzenberg L. A. and Staal F. J. (2006): Wnt signaling in the thymus is regulated by differential expression of intracellular signaling molecules. Proc. Natl. Acad. Sci. USA, 103, 3322-3326.
103. Weerkamp F., van Dongen J. J. and Staal F. J. (2006): Notch and Wnt signaling in T-lymphocyte development and acute lymphoblastic leukemia. Leukemia, 20, 1197-205.
104. Westendorf J. J., Kahler R. A. and Schroeder T. M. (2004): Wnt signaling in osteoblast and bone disease. Gene, 341, 19-39.
105. Willert K., Brown J. D., Danenberg E., Duncan A. W., Weissman I. L., Reya T., Yates J. R. and Nusse R. (2003): Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature, 423, 448-452.
106. Winklbauer R., Medina A., Swain R. K. and Steinbeisser H. (2001): Frizzled-7 signalling controls tissue separation during Xenopus gastrulation. Nature, 413, 856-860.
107. Wu B., Crampton S. P. and Hughes C. C. (2007): Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity, 26, 227-239.
108. Yang F., Li X., Sharma M., Sasaki C. Y., Longo D. L., Lim B. and Sun Z. (2002): Linking beta-catenin to androgen-signaling pathway. J. Biol. Chem., 277, 11336-11344.
109. Yang J., Wu J., Tan C. and Klein P. S. (2003): PP2A: B56? is required for Wnt/β-catenin signaling during embryonic development. Development, 130, 5569-5578.
110. Zheng X., Beissert T., Kukoc-Zivojnov N., Puccetti E., Altschmied J., Strolz C., Boehrer S., Gul H., Schneider O., Ottmann O. G., Hoelzer D., Henschler R. and Ruthardt M. (2004): Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. Blood, 103, 3535-3543.